Journal of Ovarian Research最新文献

{"title":"Effects of melatonin in polycystic ovary syndrome: is there Hippo pathway crosstalk?","authors":"Lijun Wang, Yuanyuan Jin, Yuanyuan Zhi, Zhenzhen Li, Meili Wang, Boda Wang, Xinbo Wang","doi":"10.1186/s13048-025-01642-1","DOIUrl":"https://doi.org/10.1186/s13048-025-01642-1","url":null,"abstract":"<p><strong>Objective: </strong>Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder among reproductive women, characterized by hyperandrogenism, oligo-ovulation and polycystic ovarian morphology. Incorporating complementary medicine alongside traditional lifestyle therapies for PCOS may offer additional benefits for affected women. Melatonin (MT), a hormone secreted by the pineal gland, has emerged as a potential treatment for regulating ovarian function in PCOS. However, the specific effects and underlying mechanisms of MT on PCOS need to be elucidated.</p><p><strong>Methods: </strong>This review consolidates evidence from randomized controlled trials, original research articles, systematic reviews, and meta-analyses regarding MT supplementation in PCOS, with a particular focus on its interaction with the Hippo pathway, to provide a comprehensive overview of current knowledge.</p><p><strong>Results: </strong>Current evidence suggests that MT plays a role in modulating PCOS through various mechanisms and is associated with the Hippo pathway. However, several uncertainties and key limitations in the existing literature must be addressed before these treatments can be integrated into standard clinical practice.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"101"},"PeriodicalIF":3.8,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12076993/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Malignant ascites in ovarian cancer is compatible with long-term (10 year) survival with associations to clinicopathological features.","authors":"Lok Hang Chow, Annabelle M Y Ngai, Cheuk-Yin Tang, Jacqueline H S Lee, Alfred L H Lee, Joshua J X Li, Philip P C Ip","doi":"10.1186/s13048-025-01657-8","DOIUrl":"https://doi.org/10.1186/s13048-025-01657-8","url":null,"abstract":"<p><strong>Objectives: </strong>Ovarian cancer can present with malignant ascites at initial diagnosis or disease recurrence. Although indicative of advanced disease, the prognosis of malignant ascites is reported to be favorable for ovarian cancers compared to other malignancies. This study aims to detail the survival, in particular long-term (10 year), and predictive clinicopathological factors.</p><p><strong>Methods: </strong>Cases of malignant ascites confirmed by cytology and radiologic/histologic evidence supportive of ovarian primary, over three-decades, were retrieved. Survival data was obtained, and long-term survivors were identified. Corresponding demographical, clinical, biochemical, hematological, serological, and pathological data at onset of ascites were reviewed for survival analysis.</p><p><strong>Results: </strong>Totally 277 cases were reviewed, with a mean overall survival of 69.3 months, including 27 (9.7%) long survivors. Old age, high-grade histology, low haemoglobin, serum albumin and total protein, long APTT, ECOG score ≥ 3 and prior chemotherapy associated with mortality and shorter overall survival (p = 0.03-<0.01), whereas administration of chemotherapy after onset of ascites correlated with better outcome (p < 0.01). APTT, ECOG score, total serum protein and prior chemotherapy remained independent predictors on multivariable analysis. Remission was common in long survivors, with only one (3.7%) patient dying of disease. Long survival was more common in patients with younger age, low-grade serous and endometrioid histology, lower platelet count, higher serum albumin and total protein, and patients receiving surgical treatment after ascites (p < 0.05).</p><p><strong>Conclusion: </strong>Factors predicting long survival in ovarian carcinoma patients with malignant ascites were age, histology, hematological and biochemical markers, and those with favorable clinicopathological features are compatible with long survival.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"98"},"PeriodicalIF":3.8,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12065197/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144023632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proanthocyanidins delaying the premature ovarian insufficiency through regulatory sirt1-p53-p21 signaling pathway in female germline stem cells.","authors":"Wenbo Wu, Mengying Bai, Wenli Hong, Shuyi Ling, Yuan Li, Yuqing Dai, Ruoxin Weng, Haifeng Wu, Chongyang Ren, Liujuan Zhang, Ziqiong Zhou, Zhisheng Zhong, Xinxin Fu, Yuehui Zheng","doi":"10.1186/s13048-025-01661-y","DOIUrl":"https://doi.org/10.1186/s13048-025-01661-y","url":null,"abstract":"<p><strong>Background: </strong>As women age, their ovarian follicle pool naturally declines. However, female germline stem cells (FGSCs) possess a unique ability to differentiate into oocytes and continuously self-renew, providing an effective means of delaying ovarian aging by replenishing the primordial follicle pool. Therefore, activating FGSCs is critical in reshaping and safeguarding ovarian function.</p><p><strong>Methods: </strong>In this study, we investigated the biological activity of proanthocyanidins (PACs), natural antioxidants that exhibit anti-aging and anti-inflammatory properties beneficial for both male and female reproduction. Our in vivo and in vitro experiments demonstrate that PACs promote FGSCs proliferation while delaying ovarian aging.</p><p><strong>Results: </strong>PACs increase the number of primordial follicles, primary follicles, corpus luteum while reducing cystic follicles, and elevate estradiol (E₂) levels along with anti-mullerian hormone (AMH) concentration levels in mice. Additionally, PACs significantly boost FGSCs proliferation time- and dose-dependently by upregulating mRNA & protein expressions for FGSCs-specific markers such as MVH and OCT4 while downregulating p53/p21 via activation of silent information regulator 1(Sirt1) signaling pathway. The effects of PACs on FGCSs were found to be impeded by the Sirt1 inhibitor EX527.</p><p><strong>Conclusion: </strong>PACS delay premature ovarian insufficiency (POI) through regulating the Sirt1-p53-p21 signaling pathway involving FGSCs.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"97"},"PeriodicalIF":3.8,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12065257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thrombospondin-1 induces CD8⁺ T cell exhaustion and immune suppression within the tumor microenvironment of ovarian cancer.","authors":"Haiyan Liang, Suwei Zhang","doi":"10.1186/s13048-025-01668-5","DOIUrl":"https://doi.org/10.1186/s13048-025-01668-5","url":null,"abstract":"<p><strong>Background: </strong>Ovarian cancer (OC) progression is heavily influenced by the tumor microenvironment (TME), where immune suppression plays a critical role. This study explores the role of thrombospondin-1 (THBS1) in regulating tumor-associated macrophages (TAMs), T cell exhaustion, and immune checkpoint expression, as well as its transcriptional regulation by SNF2H.</p><p><strong>Methods: </strong>We analyzed THBS1 expression and its clinical significance using publicly available datasets (TCGA-OV, GSE14407) and tissue microarrays containing OC and adjacent normal tissues. In vitro functional studies were conducted using OC cell lines (SKOV3, A2780) and co-cultures with macrophages. Chromatin immunoprecipitation (ChIP) assays and RNA interference were employed to investigate SNF2H-mediated transcriptional regulation of THBS1. In vivo, the role of THBS1 in immune suppression was validated using mouse tumor models.</p><p><strong>Results: </strong>THBS1 was significantly overexpressed in OC tissues and associated with poor prognosis. High levels of THBS1 correlated with increased TAM infiltration, M2 macrophage polarization, and upregulation of immune checkpoints PD-L1 and GAL-3, which contribute to T cell exhaustion. Functional assays demonstrated that THBS1 promotes macrophage recruitment and induces M2 polarization through TGF-β1 and IL-4 signaling. Additionally, ChIP assays identified SNF2H as a transcriptional regulator of THBS1, contributing to its overexpression. In vitro targeting of THBS1 reduced TAM-mediated immune suppression and restored T cell cytotoxicity.</p><p><strong>Conclusion: </strong>This study positions THBS1 as a key regulator of the OC TME, linking TAM recruitment and polarization to CD8⁺ T cell exhaustion via immune checkpoint modulation. By identifying SNF2H as a transcriptional regulator of THBS1, we offer new insights into its epigenetic dysregulation and suggest potential therapeutic strategies to reprogram the TME and improve the effectiveness of immunotherapy.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"99"},"PeriodicalIF":3.8,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12065243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging nanotechnologies and their role in early ovarian cancer detection, diagnosis and interventions.","authors":"Mega Obukohwo Oyowvi, Kehinde Henrietta Babawale, Adedeji David Atere, Benneth Ben-Azu","doi":"10.1186/s13048-025-01678-3","DOIUrl":"10.1186/s13048-025-01678-3","url":null,"abstract":"<p><p>Ovarian cancer presents a significant public health challenge, often being diagnosed at advanced stages due to the limitations of current detection methods. This systematic review addresses the urgent need for innovative approaches to enhance early detection and diagnosis of ovarian cancer. We systematically evaluate recent advancements in nanotechnology, focusing specifically on their novel applications and potential in comparison to traditional diagnostic modalities. Our analysis encompasses a wide range of studies investigating nanoparticles, biosensors, advanced imaging techniques, and biomarker detection platforms, with an emphasis on evaluating key performance indicators such as detection rates, turnaround times, and the accuracy of distinguishing cancerous from non-cancerous tissues. Our findings indicate that nanotechnology-based approaches have the potential to significantly improve early detection capabilities for ovarian cancer. Notably, studies on nanoparticle-based imaging techniques and biosensors consistently demonstrate high sensitivity and specificity for identifying ovarian cancer biomarkers, with detection rates exceeding 90% reported for early-stage cancers in several instances. This review underscores the promise of emerging nanotechnologies to transform the landscape of early detection and diagnosis, offering a pathway toward earlier diagnoses, enhanced therapeutic interventions, and improved patient outcomes. We advocate for future research dedicated to the translational efforts required to move these technologies from bench to bedside, ensuring their effectiveness is validated across diverse clinical populations.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"96"},"PeriodicalIF":3.8,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12057071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144025316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Restoration of TP53 strategy via specific nanoparticles for ovarian cancer therapy.","authors":"Menglei Zhang, Yuanyuan Gu, Fang Shen, Yingxin Gong, Zheng Gu, Keqin Hua, Guannan Zhou, Jingxin Ding","doi":"10.1186/s13048-025-01672-9","DOIUrl":"https://doi.org/10.1186/s13048-025-01672-9","url":null,"abstract":"<p><p>The p53 tumor suppressor gene, a master regulator of diverse cellular pathways, is frequently altered in various cancers. Loss of function in tumor suppressor genes is commonly associated with the onset/progression of cancer and treatment resistance. Currently, approaches for restoration of TP53 expression, including small molecules and DNA therapies, have yielded progressive success, but each has formidable drawbacks. Here, we introduced an endogenous nanoplatform to effectively deliver the TP53 protein. Briefly speaking, the endogenous TP53 proteins were fused by the Lamp2b and loaded into extracellular vesicles-based nanoparticles, which could markedly restore the TP53 expression in natural TP53-deficient ovarian cancer (OCs) and subsequently inhibit cell proliferation as well as induce cell apoptosis. Moreover, a well-known biotin streptavidin binding strategy was used to confer the nanoplatform targeting ability. Since mesothelin (MSLN) expressed highly in ovarian cancer, the anti-MSLN nanoplatform were engineered to deliver TP53 proteins to MSLN ovarian cancer and exert the anti-tumor ability. Our findings indicated that restoration of tumor suppressors by the targeting nanoplatform could be promising nanotechnology approaches for potential ovarian cancer treatment.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"95"},"PeriodicalIF":3.8,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12054137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment with trypLE before freezing improves thawing integrity and functionality of sheep ovarian tissue.","authors":"Alicia Marco, Marta Gargallo, Jesús Ciriza, María Royo-Cañas, Alejandro Ibáñez-Deler, Ana Rosa Remacha, María Fons-Contreras, Clara Malo","doi":"10.1186/s13048-025-01593-7","DOIUrl":"https://doi.org/10.1186/s13048-025-01593-7","url":null,"abstract":"<p><strong>Objective: </strong>To study innovative approaches to ovarian tissue cryopreservation, a critical issue for fertility preservation in pediatric cancer patients. Despite historical attempts, recent advances in cancer treatment have underscored the urgent need for more effective and reliable ovarian tissue cryopreservation methods. Our research aims to evaluate if decreasing the rigidity of stroma before cryopreservation by investigating pre-treatments with enzymes can enhance the quality of ovarian tissue post-thawing.</p><p><strong>Design: </strong>Our research evaluated the use of five commonly used enzymes to disaggregate tissue (trypLE, collagenase, dispase, accutase and hyaluronidase) before freezing ovarian tissue to decrease rigidity and facilitate cryopreservation. Sheep ovaries, with high similarity to human ovaries, were used as an animal model. Tissue structure, cell proliferation, apoptosis and viability were assessed before and after thawing.</p><p><strong>Results: </strong>Our findings showed that enzymatic treatment with trypLE before freezing offered immediate benefits post-thawing with the highest viability values and percentage of intact follicles. A decrease in viability was observed after thawing and culturing the samples. The pretreatment with accutase damaged the tissue severely with also the lowest viability values. Ki67-positive follicles and stromal cells were observed in fresh samples, but only trypLE and hyaluronidase maintained Ki67-positive antral follicles after 2 days culture. Besides, only trypLE maintained all follicles negative to caspase-3 after thawing, and 7 days after culture primordial follicles were apoptotic in all treatments apart from trypLE.</p><p><strong>Conclusion: </strong>our findings suggest that trypLE pretreatment could provide a beneficial approach for maintaining the functions and viability of cryopreserved ovaries after thawing. Further research is needed to fully understand their impact and optimize cryopreservation protocols in this important clinical context.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"94"},"PeriodicalIF":3.8,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12048971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beautiful and regular vascularization in a borderline ovarian seromucinous tumor detected by microvascular imaging.","authors":"Luying Gao, Mei Yu, Dan Wang, Na Su","doi":"10.1186/s13048-025-01675-6","DOIUrl":"10.1186/s13048-025-01675-6","url":null,"abstract":"<p><strong>Background: </strong>In clinical practice, borderline seromucinous ovarian tumor (SMBT) is hard to differentiate preoperatively on ultrasound.</p><p><strong>Case: </strong>We presented a case of SMBT. In this case, microvascular imaging, particularly three-dimensional (3D) microvascular imaging of ultrasound showed the regular distribution of vascularity along the axis of the papillary trunk and branches.</p><p><strong>Conclusion: </strong>Microvascular imaging helped improve identify vascularity distribution in the papillary of SMBT and may improve our ability to differentiate SMBTs.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"92"},"PeriodicalIF":3.8,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12046836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144030576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance of circulating EpCAM+ and CD45+ extracellular vesicles in platinum-sensitivity in high-grade serous ovarian cancer: a pilot study.","authors":"Chiara Tersigni, Marianna Onori, Alexia Buzzonetti, Arianna Ferrante, Andrea Fattorossi, Alessandra Battaglia, Giacomo Corrado, Caterina Neri, Giuliana Beneduce, Fabio Sannino, Alessandro Petrecca, Giovanni Scambia, Anna Fagotti","doi":"10.1186/s13048-025-01656-9","DOIUrl":"https://doi.org/10.1186/s13048-025-01656-9","url":null,"abstract":"<p><strong>Background: </strong>Platinum-resistant high-grade serous ovarian cancer (HGSOC) is a fatal disease. The main goal of current study is to develop new strategies to predict platinum resistance, moving towards personalized therapy. Currently, there are no validated biomarkers able to predict at diagnosis platinum resistance. Circulating tumor-derived extracellular vesicles (EVs) represent a liquid biopsy of the tumor of origin and reflect its biological profile. EpCAM-expressing EVs are largely used biomarkers of epithelial cancers in translational research. Aim of this study was to quantify, by nano-flow cytometry, circulating EpCAM+ EVs in patients with histologically confirmed diagnosis of HGSOC FIGO stage III/IV, before and after intravenous administration of the first dose of chemotherapy with paclitaxel and carboplatin, and correlate EVs levels to platinum-sensitivity. As comparison, leukocyte-derived EVs were also assessed using the pan-leukocyte marker CD45.</p><p><strong>Results: </strong>Patients with platinum-sensitive HGSOC showed significantly lower pre-chemotherapy circulating levels of both EpCAM+ and CD45+ EVs compared to platinum-resistant cases (p<0.01). Platinum-sensitive patients displayed significantly higher levels of circulating EpCAM+ and CD45+ EVs 21 days post administration of the first dose of chemotherapy compared to pre-treatment levels (p<0.05 and p<0.01, respectively). Platinum-resistant and platinum-refractory patients showed significantly higher EpCAM⁺CD45⁺ EVs levels than platinum-sensitive patients (p<0.01, p<0.05, respectively).</p><p><strong>Conclusions: </strong>Tumor-derived EVs are valuable candidate biomarkers for early prediction of platinum resistance and need to be investigated in larger prospective clinical studies.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"93"},"PeriodicalIF":3.8,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12046641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of Chinese herbal medicine in diminished ovarian reserve management.","authors":"Xiaoyu Zhang, Na Zhang, Zhibin Dong, Hao Sun, Zhihao Diao, Yujie Li, Dongqing Du, Yuxia Ma","doi":"10.1186/s13048-025-01669-4","DOIUrl":"https://doi.org/10.1186/s13048-025-01669-4","url":null,"abstract":"<p><p>Diminished Ovarian Reserve (DOR) is characterized by a reduction in the number of available follicles in the ovaries, leading to hormonal imbalances, decreased ovarian reserve, and reduced fertility. Clinically, it presents with elevated follicle-stimulating hormone (FSH) levels, decreased anti-Müllerian hormone (AMH) levels, and a lower antral follicle count (AFC). In recent years, Traditional Chinese Medicine (TCM) has gained recognition for its multi-target, holistic regulation in treating DOR, offering broad therapeutic effects with minimal side effects. This review aims to summarize the mechanisms and clinical efficacy of Chinese herbal medicine (CHM) formulas and active compounds in the treatment of DOR, providing theoretical support for their clinical application and future research. A systematic literature search was conducted from June 2019 to June 2024, and 12 clinical studies along with 38 basic research papers were selected. The findings suggest that CHM formulas primarily act by counteracting oxidative stress, regulating immune defense, modulating sex hormone secretion via the hypothalamic-pituitary-ovarian axis, and inhibiting excessive apoptosis of ovarian granulosa cells. This review highlights the therapeutic potential of TCM for improving ovarian function, regulating endocrine balance, and alleviating DOR symptoms, offering valuable insights for clinical practice and research.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"90"},"PeriodicalIF":3.8,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042416/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144018195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}